Emtricitabine And Tenofovir Alafenamide

Introduction Overview

Generic Name

emtricitabine and tenofovir alafenamide

Brand Name

Descovy

Dosage Form

oral tablet (200 mg/25 mg, 120 mg/15 mg)

Drug Class

Antiviral combinations

Pharmacokinetics

Absorption: Descovy combines emtricitabine and tenofovir alafenamide (TAF) in a single oral tablet, both of which exhibit rapid and efficient gastrointestinal absorption. Emtricitabine achieves peak plasma concentrations approximately 1-2 hours after oral administration, demonstrating high oral bioavailability independent of food intake. Tenofovir alafenamide, a prodrug of tenofovir, is efficiently absorbed and undergoes intracellular conversion to the active tenofovir diphosphate, thereby enabling potent antiviral activity at lower plasma concentrations compared to its predecessor tenofovir disoproxil fumarate (TDF). Food does not significantly affect the absorption of Descovy, allowing administration with or without meals. Factors such as gastrointestinal pH, motility, and concurrent medications may impact absorption to a minor degree, but clinical significance is limited owing to the drug’s favorable pharmacokinetic profile.

Distribution: After systemic absorption, emtricitabine distributes widely throughout body tissues and fluids, including the genital tract and cerebrospinal fluid (CSF), with a volume of distribution approximating 1.4 L/kg, indicating extensive extravascular distribution. Tenofovir alafenamide exhibits preferential distribution within lymphoid cells, the primary site of HIV replication, owing to its intracellular conversion to the active metabolite tenofovir diphosphate. Plasma protein binding for emtricitabine is negligible (<4%), while for tenofovir alafenamide it is about 80%, though the intracellular active form is largely confined within target cells, reducing systemic exposure and potential toxicity. The drug crosses the placenta and is excreted in breast milk, cautioning use in pregnant and breastfeeding patients.

Metabolism: Emtricitabine undergoes limited hepatic metabolism, with the majority eliminated unchanged renally. Tenofovir alafenamide is metabolized intracellularly by cathepsin A to tenofovir, which is then phosphorylated to tenofovir diphosphate, the active moiety responsible for antiviral activity. This intracellular metabolism allows for lower plasma concentrations of tenofovir, reducing systemic toxicity. Hepatic cytochrome P450 enzymes have no significant role in the metabolism of either drug component, minimizing the potential for cytochrome-mediated drug-drug interactions. Minor metabolic pathways may contribute to elimination but do not substantially affect pharmacokinetics or clinical outcomes.

Elimination: Emtricitabine is primarily eliminated via renal excretion through a combination of glomerular filtration and active tubular secretion, with about 86% excreted unchanged in urine and an elimination half-life of approximately 10 hours. Dose adjustments may be required in patients with renal impairment due to alterations in clearance. Tenofovir alafenamide’s active metabolite tenofovir diphosphate has intracellular half-life ranging from 39 to 77 hours, enabling once-daily dosing. Plasma elimination of tenofovir occurs predominantly via renal excretion by glomerular filtration and active tubular secretion. Because tenofovir alafenamide results in lower systemic tenofovir exposure compared to TDF, it demonstrates better renal safety profiles. Monitoring of renal function during therapy is recommended, especially in patients with underlying kidney disease or concomitant nephrotoxic agents.

Dosage Forms

Available Dosage Forms: Descovy is formulated as film-coated oral tablets combining fixed doses of emtricitabine and tenofovir alafenamide. The available tablet strengths include:
- Descovy 200 mg/25 mg: contains 200 mg emtricitabine and 25 mg tenofovir alafenamide per tablet.
- Descovy 120 mg/15 mg: contains 120 mg emtricitabine and 15 mg tenofovir alafenamide per tablet.
The tablets are film-coated with excipients including croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and specific coating agents such as indigo carmine aluminum lake for the 200 mg/25 mg formulation and polyvinyl alcohol components for the 120 mg/15 mg tablets.

Dosages for Adults and Adolescents: For HIV-1 treatment, the recommended dosage of Descovy varies based on patient weight:
- Adults and adolescents weighing ≥35 kg (≥77 pounds): one 200 mg/25 mg tablet once daily.
- Adolescents and children weighing 25 to <35 kg (55 to <77 pounds): one 200 mg/25 mg tablet once daily.
- Children weighing 14 to <25 kg (30.8 to <55 pounds): one 120 mg/15 mg tablet once daily.
For HIV-1 pre-exposure prophylaxis (PrEP) in adults and adolescents ≥35 kg, dosing is one 200 mg/25 mg tablet once daily.

Specific Patient Populations: In patients with renal impairment, dosing adjustments are recommended based on creatinine clearance due to predominant renal elimination of both components. Descovy is not recommended for patients with estimated creatinine clearance below 30 mL/minute or patients on hemodialysis, as pharmacokinetic data is limited in these populations. For patients undergoing dialysis, administration is advised after dialysis. Special consideration is given during pregnancy and breastfeeding, although data remain limited; Descovy should be used if benefits outweigh risks, with close monitoring advised. Pediatric dosing is weight-based as indicated above, with careful evaluation by healthcare providers. No dosage adjustment is required based on hepatic impairment, but caution is advised.

Overall, Descovy offers convenient once-daily oral dosing in fixed-dose combinations, facilitating adherence in both treatment and prevention of HIV.

Mechanism Of Action

Descovy's antiviral efficacy derives from its two active components, emtricitabine and tenofovir alafenamide, both of which are nucleoside reverse transcriptase inhibitors (NRTIs). Their primary molecular mechanism involves the interruption of HIV-1 viral replication by targeting the viral reverse transcriptase enzyme, a key catalyst for converting viral RNA into DNA necessary for integration into the host genome. Emtricitabine is a cytidine analog, while tenofovir alafenamide, after intracellular metabolism, acts as an adenosine monophosphate analog. Both compounds competitively inhibit the incorporation of natural nucleosides into nascent viral DNA.

Within infected cells, emtricitabine and tenofovir diphosphate (the active metabolite of tenofovir alafenamide) are incorporated into viral DNA by reverse transcriptase, causing premature termination of the DNA chain due to the absence of a 3'-OH group necessary for chain elongation. This biochemical blockade prevents the synthesis of complete viral DNA, thereby halting the ability of HIV-1 to replicate and infect new cells. The selective affinity of these agents for viral reverse transcriptase, as opposed to host DNA polymerases, underpins their antiviral specificity and relative tolerability.

Cellular pathway targeting includes efficient intracellular uptake facilitated by membrane transporters, followed by phosphorylation activation steps mediated by host kinases. Tenofovir alafenamide's prodrug design allows it to remain stable in plasma but efficiently taken up by lymphoid cells and lymphatic tissues—the primary reservoirs for HIV—where it is enzymatically converted to active tenofovir diphosphate. This targeted intracellular delivery enhances therapeutic potency and reduces exposure associated toxicities seen with earlier formulations such as tenofovir disoproxil fumarate.

Clinically, the combined use of emtricitabine and tenofovir alafenamide in Descovy leads to substantial suppression of plasma HIV-1 RNA levels, decreased viral burden, and reduced risk of disease progression when used with other antiretroviral agents. The fixed-dose once-daily co-formulation enhances adherence and viral suppression efficacy. Comparative studies have demonstrated that Descovy provides non-inferior antiviral efficacy to older tenofovir disoproxil fumarate-based regimens but with improved renal and bone safety profiles owing to lower systemic tenofovir exposure. Research and clinical trials, including the DISCOVER trial, have validated Descovy’s effectiveness in both HIV-1 treatment and pre-exposure prophylaxis scenarios, supporting its integral role in modern antiretroviral therapy strategies.

Pharmacological Actions

Inhibition of HIV-1 reverse transcriptase enzyme activity via nucleoside analog incorporation.
Prevention of viral RNA conversion to DNA, blocking HIV replication and infection propagation.
Intracellular delivery and activation of tenofovir alafenamide to tenofovir diphosphate, a potent antiretroviral agent.
Reduction of plasma HIV-1 viral loads when used in combination antiretroviral therapy.
Provision of pre-exposure prophylaxis (PrEP) by preventing HIV infection in high-risk individuals.
Selective targeting of lymphoid tissues to maximize antiviral effect while minimizing systemic toxicity.
Improved renal safety compared to tenofovir disoproxil fumarate due to reduced plasma tenofovir exposure.
Combination therapy reducing potential for resistance development through dual NRTI action.
Once-daily dosing enhances patient adherence and sustained viral suppression.
Non-involvement of cytochrome P450 enzymes reduces drug-drug interaction risks.
Amelioration of viral mutation effects through comprehensive reverse transcriptase blockade.

Therapeutic Or Clinical Uses

Treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg, in combination with other antiretroviral agents.
Pre-exposure prophylaxis (PrEP) to reduce risk of HIV-1 infection in adults and adolescents weighing at least 35 kg.
Used as a once-daily oral tablet simplifying complex antiretroviral regimens.
Associated with improved renal and bone safety compared to older tenofovir formulations, benefiting patients with comorbidities.
Treatment option in patients with mild to moderate renal impairment with appropriate monitoring and dosage adjustment.
Alternative PrEP choice for individuals intolerant or contraindicated to tenofovir disoproxil fumarate-containing regimens.
Component of combination antiviral therapy regimens optimized to reduce viral resistance emergence.
Recommended in patients requiring fixed-dose, oral antiretroviral therapy to enhance adherence.
An option for HIV-1 infection management in adolescents, promoting early initiation of effective therapy.
Used in populations at risk for HIV exposure through sexual contact and injection drug use, contingent on adherence.
Treatment regimens incorporating Descovy align with latest HIV treatment guidelines emphasizing efficacy and safety.
Applicable to patients with coexistent hepatitis B infection, with caution and hepatic monitoring.
Utilized under medical supervision for tailored HIV treatment plans balancing efficacy and tolerability.
Provides a therapeutic alternative with a distinct pharmacokinetic profile favoring reduced systemic toxicity.

Side Or Adverse Effects

Nausea, reported commonly in patients undergoing HIV-1 treatment with Descovy.
Diarrhea, particularly frequent among users employing Descovy for HIV PrEP.
Headache and dizziness, varying in intensity and frequency among individuals.
Sleep disturbances including insomnia and vivid or strange dreams.
Fatigue and feelings of depression or general malaise.
Gastrointestinal discomfort such as stomach pain.
Weight loss observed in some individuals during HIV-1 therapy with Descovy.
Skin rash and hypersensitivity reactions, potentially warranting medical attention.
Serious adverse reactions including lactic acidosis characterized by muscle pain, difficulty breathing, and severe fatigue.
Potential for severe liver toxicity, including rare fatal hepatic failure — watch for jaundice or dark urine.
Worsening or flare-ups of hepatitis B virus infection upon treatment initiation or discontinuation.
Risk of new or worsening renal impairment including acute kidney injury.
Immune reconstitution inflammatory syndrome (IRIS), manifesting as inflammatory responses to latent infections.
Hypersensitivity reactions including anaphylaxis, bronchospasm, and angioedema requiring immediate intervention.
Potential for mild to moderate increases in serum creatinine without impacting glomerular filtration rate significantly.

Precautions

Confirm HIV-negative status before initiating Descovy for PrEP to avoid monotherapy in infected individuals.
Baseline and ongoing assessment of renal function due to potential nephrotoxic effects.
Screen for hepatitis B infection prior to initiation; monitor liver function and HBV viral load during and after therapy.
Adherence to dose schedule is critical to maintain therapeutic effectiveness and prevent resistance.
Avoid abrupt discontinuation to prevent hepatitis B virus flare in coinfected patients.
Use caution in patients with pre-existing kidney disease or risk factors for renal impairment.
Inform healthcare provider of all concomitant medications to manage potential drug interactions.
Monitor for symptoms of lactic acidosis and hepatotoxicity, and seek prompt medical evaluation if symptoms occur.
Pregnancy: limited data available, necessitating careful risk-benefit discussion with healthcare provider.
Breastfeeding is contraindicated in HIV-positive mothers on Descovy due to risk of viral transmission.
Do not use with other medications containing emtricitabine, tenofovir, lamivudine, or adefovir to avoid overdose.
Practice safer sex and regular HIV testing as Descovy alone does not prevent HIV infection fully.
Advise patients on potential neuropsychiatric side effects including depression or insomnia.
Adjust dosing or avoid use in severe renal impairment or patients on hemodialysis due to insufficient data.
Regularly assess for opportunistic infections as immune reconstitution may unmask latent infections.

Warnings

Risk of severe lactic acidosis and hepatomegaly with steatosis; life-threatening and requires emergency care.
Potential for worsening hepatitis B infection upon discontinuation of Descovy; requires monitoring or prophylactic treatment.
Immune reconstitution inflammatory syndrome may unmask subclinical infections following initiation.
Monitor renal function as Descovy may cause acute kidney injury or decline in renal function.
Risk of hypersensitivity reactions including severe skin reactions and anaphylaxis.
Not recommended for HIV-1 monoinfection treatment without combination antiretroviral therapy.
Not approved for HIV prevention in individuals assigned female at birth at risk through vaginal sex.
Potential neuropsychiatric adverse effects including depression, insomnia, and abnormal dreams.
Avoid concomitant use with other drugs containing similar active components to prevent toxicity.
Drug resistance can develop if doses are missed or therapy is interrupted.
Not established safety and efficacy in patients with severe hepatic impairment.
Avoid abrupt discontinuation to prevent disease flare and resistance.
Use with caution in patients with history of osteoporosis or at high risk for bone disease.
May contribute to weight changes, necessitating monitoring in long-term therapy.
Pregnancy safety profile is not fully established; involve patients in registry studies when possible.

Contraindication

Known hypersensitivity to emtricitabine, tenofovir alafenamide, or any component of the formulation.
Concurrent use with other antiretroviral agents containing emtricitabine, tenofovir, lamivudine, or adefovir.
Patients with unknown or positive HIV-1 status taking Descovy solely for pre-exposure prophylaxis.
Severe renal impairment including patients requiring dialysis due to insufficient pharmacokinetic data.
Hypersensitivity or allergic reactions history to any nucleoside reverse transcriptase inhibitors.
Use in individuals assigned female at birth at risk for HIV infection via vaginal sex when used for PrEP.
Patients with evidence of lactic acidosis or hepatic impairment related to prior antiretroviral therapy.
Concurrent administration with competing nephrotoxic agents without close monitoring.
Known intolerance or idiosyncratic reaction to any inactive ingredients in the tablets.
Patients unable to comply with HIV status monitoring or adherence requirements for PrEP.
Patients with severe hepatic dysfunction or liver failure where drug metabolism cannot be assured.
Pediatric patients weighing less than 14 kg due to lack of established safety and efficacy data.
Use during breastfeeding in HIV-infected women due to risk of HIV transmission to the infant.
Combination with drugs that significantly interact to alter emtricitabine or tenofovir pharmacokinetics.
Known history of severe depression or psychiatric illness without proper medical oversight.

Drug Interactions

Co-administration with nephrotoxic drugs (e.g., NSAIDs like ibuprofen, naproxen) may increase risk of renal toxicity.
Anticonvulsants such as carbamazepine, oxcarbazepine, phenytoin, and phenobarbital may reduce efficacy by inducing metabolic pathways.
Concurrent use with other antiretroviral agents treating hepatitis C or HIV requires careful regimen adjustment.
Potential interaction with drugs affecting renal tubular secretion leading to altered elimination of Descovy components.
Limited or no significant cytochrome P450-based interactions due to non-involvement of these enzymes in metabolism.
Co-administration with herbal supplements or vitamins may affect drug absorption or adherence but lacks robust data.
Probenecid or rifampin may modify plasma concentrations of tenofovir or emtricitabine by affecting renal transporters.
Certain acid-reducing agents have minimal effect but monitoring is recommended for absorption changes.
Interactions with immunosuppressants used in transplant patients may necessitate dosage monitoring of all agents.
Combination with other NRTIs or similar agents can increase toxicity risk and is contraindicated.
No significant interactions with contraceptives noted; however, adherence and monitoring remain essential.
Monitoring recommended when used with drugs that impact kidney function or cause electrolyte disturbances.
Potential reduced efficacy if combined with drugs that impair gastrointestinal absorption.
No significant interaction with commonly used antidepressants or sleep agents but vigilance for neuropsychiatric effects advised.
Drug interaction checker tools should be employed to evaluate individual patient polypharmacy risks.

Preparations Of The Drug

Descovy oral tablets available in two fixed-dose combinations: 200 mg emtricitabine/25 mg tenofovir alafenamide and 120 mg emtricitabine/15 mg tenofovir alafenamide.
Film-coated tablets designed for once-daily oral administration with or without food to facilitate dosing adherence.
Tablets include inactive ingredients such as croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and specific film coat excipients for stability and bioavailability.
Packaging typically includes blister packs or bottles maintaining room temperature stability.
Manufactured and marketed by Gilead Sciences, Inc., with strict quality control to ensure consistent drug potency and purity.
Prescribed as a single tablet regimen to reduce pill burden and simplify antiretroviral therapy regimens.
Available with specific coatings: 200 mg/25 mg tablets contain indigo carmine aluminum lake; 120 mg/15 mg tablets contain polyvinyl alcohol and titanium dioxide.
Storage instructions recommend keeping tablets in original containers at room temperature away from moisture and heat.
Guidelines advise against splitting, crushing, or altering tablet form to maintain pharmacokinetic properties.
Distribution includes comprehensive prescription labeling with dosage guidelines, warnings, and patient information leaflets.
Preparations designed for oral use exclusively; not formulated for other routes of administration.
Manufacture adheres to FDA regulations and pharmacopeial standards to ensure safety and efficacy.
Copackaged with medication guides emphasizing adherence, side effects, and drug interaction risks.
Patient assistance and co-pay programs available to support access and affordability.
Preparations are proprietary and patented formulations ensuring optimized delivery and reduced toxicity.